• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 144 filed by Amylyx Pharmaceuticals Inc.

    12/1/25 4:05:01 PM ET
    $AMLX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AMLX alert in real time by email
    Form 144 Filer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 144

    NOTICE OF PROPOSED SALE OF SECURITIES
    PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

    FORM 144

    144: Filer Information

    Filer CIK
    0001326969
    Filer CCC
    XXXXXXXX
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST

    Submission Contact Information

    Name
    Phone
    E-Mail Address

    144: Issuer Information

    Name of Issuer
    Amylyx Pharmaceuticals, Inc.
    SEC File Number
    001-41199
    Address of Issuer
    43 Thorndike St.
    Cambridge
    MASSACHUSETTS
    02141
    Phone
    617-682-0917
    Name of Person for Whose Account the Securities are To Be Sold
    Bedrosian Camille L
    See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

    Relationship to Issuer
    Officer

    144: Securities Information

    Title of the Class of Securities To Be SoldName and Address of the BrokerNumber of Shares or Other Units To Be SoldAggregate Market ValueNumber of Shares or Other Units OutstandingApproximate Date of SaleName the Securities Exchange
    Common
    Morgan Stanley Smith Barney LLC
    1 New York Plaza
    8th Floor
    New York � NY � 10004
    65809441919033912/01/2025
    NASDAQ


    Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

    144: Securities To Be Sold

    Title of the ClassDate you AcquiredNature of Acquisition TransactionName of Person from Whom AcquiredIs this a Gift?Date Donor AcquiredAmount of Securities AcquiredDate of PaymentNature of Payment *
    Common12/01/2025Vesting of Restricted Stock UnitsIssuerCheckbox not checked1458312/01/2025N/A

    * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



    Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

    144: Securities Sold During The Past 3 Months

    Name and Address of SellerTitle of Securities SoldDate of SaleAmount of Securities SoldGross Proceeds
    Bedrosian Camille L
    43 Thorndike St.
    Cambridge � MA � 02141
    Common09/30/202512039175517

    144: Remarks and Signature

    Remarks
    This sale represents shares sold solely to satisfy tax withholding obligations arising from the vesting of restricted stock units.
    Date of Notice
    12/01/2025

    ATTENTION:

    The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
    Signature
    /s/ Joshua B. Cohen, as Attorney in Fact

    ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

    Get the next $AMLX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AMLX

    DatePrice TargetRatingAnalyst
    7/10/2025$10.00Buy
    Goldman
    6/24/2025$17.00Buy
    Guggenheim
    6/17/2025$12.00Buy
    Citigroup
    5/30/2025Buy
    TD Cowen
    4/7/2025$7.00Neutral → Outperform
    Mizuho
    11/18/2024$3.00 → $11.00Neutral → Outperform
    Robert W. Baird
    10/23/2024$4.20 → $10.00Neutral → Buy
    BofA Securities
    3/18/2024$32.00 → $4.00Buy → Neutral
    Mizuho
    More analyst ratings

    $AMLX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Zeiher Bernhardt G bought $37,005 worth of shares (10,000 units at $3.70) (SEC Form 4)

    4 - Amylyx Pharmaceuticals, Inc. (0001658551) (Issuer)

    3/24/25 4:15:37 PM ET
    $AMLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Frates James M bought $101,368 worth of shares (40,000 units at $2.53), increasing direct ownership by 21% to 233,464 units (SEC Form 4)

    4 - Amylyx Pharmaceuticals, Inc. (0001658551) (Issuer)

    9/16/24 5:30:37 PM ET
    $AMLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Firestone Karen bought $106,590 worth of shares (50,000 units at $2.13), increasing direct ownership by 1,000% to 55,000 units (SEC Form 4)

    4 - Amylyx Pharmaceuticals, Inc. (0001658551) (Issuer)

    9/9/24 4:05:06 PM ET
    $AMLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMLX
    SEC Filings

    View All

    SEC Form 144 filed by Amylyx Pharmaceuticals Inc.

    144 - Amylyx Pharmaceuticals, Inc. (0001658551) (Subject)

    12/1/25 4:05:01 PM ET
    $AMLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Amylyx Pharmaceuticals Inc.

    SCHEDULE 13G/A - Amylyx Pharmaceuticals, Inc. (0001658551) (Subject)

    11/14/25 4:10:36 PM ET
    $AMLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Amylyx Pharmaceuticals Inc.

    SCHEDULE 13G/A - Amylyx Pharmaceuticals, Inc. (0001658551) (Subject)

    11/14/25 4:00:03 PM ET
    $AMLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMLX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Amylyx Pharmaceuticals Announces New Safety and Tolerability Cohort 1 Data of AMX0114 in ALS from First-in-Human LUMINA Trial

    - AMX0114 was generally well-tolerated, with no treatment-related serious adverse events - Amylyx will proceed with opening enrollment of second cohort - Data are being presented at the 36th International Symposium on ALS/MND Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) ("Amylyx" or the "Company") today announced the presentation of early safety and tolerability data from its Phase 1 LUMINA trial of AMX0114 and results from ongoing work characterizing biomarkers of AMX0114 target engagement at the 36th International Symposium on ALS/MND (MNDA) held from December 5-7 in San Diego, California. AMX0114 was generally well-tolerated in LUMINA trial participants enrolled in cohort 1 (n=12), with

    12/5/25 9:00:00 AM ET
    $AMLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amylyx Pharmaceuticals to Present at Upcoming Investor Conferences

    Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) ("Amylyx" or the "Company") today announced that management will present at the following upcoming conferences, which are being conducted in-person: Guggenheim 2nd Annual Healthcare Innovation Conference: Fireside chat on Monday, November 10, 2025, at 4:30pm ET in Boston, Massachusetts 8th Annual Evercore Healthcare Conference: Fireside Chat on Tuesday, December 2, 2025, at 8:20am ET in Coral Gables, Florida Citi's 2025 Global Healthcare Conference: Fireside Chat on Wednesday, December 3, 2025, at 4:00pm ET in Miami, Florida A live webcast of each fireside chat can be accessed under "Events and Presentations" in the Investor section of

    11/3/25 9:00:00 AM ET
    $AMLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amylyx Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 6, 2025

    Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) ("Amylyx" or the "Company") will report its third quarter 2025 financial results on Thursday, November 6, 2025. Amylyx' senior management team will host a conference call and audio webcast at 8:00 a.m. ET to discuss the financial results and other company updates. To access the conference call, please dial +1 (888) 880-3330 (U.S. & Canada) or +1 (646) 357-8766 (international) at least 10 minutes prior to the start time and ask to be joined into the Amylyx Pharmaceuticals call. A live audio webcast of the call will be available under "Events and Presentations" in the Investor section of the Company's website, https://investors.amylyx.com/events-pr

    10/30/25 9:00:00 AM ET
    $AMLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMLX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    September 29, 2022 - FDA Approves New Treatment Option for Patients with ALS

    For Immediate Release: September 29, 2022 The U.S. Food and Drug Administration today approved Relyvrio (sodium phenylbutyrate/taurursodiol) to treat patients with amyotrophic lateral sclerosis (ALS), commonly referred to as Lou Gehrig’s disease.  “This approval provides another important treatment option for ALS, a life-threatening disease that currently has no cure,” said Billy Dunn, M.D., director of the Off

    9/29/22 5:02:14 PM ET
    $AMLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    September 2, 2022 - FDA Roundup: September 2, 2022

    For Immediate Release: September 02, 2022 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:   On Thursday, the FDA published the FDA Voices: “Using A Whole-Of-Governments Approach to Combating Illicit Health Products,” by Cathy Hermsen, Assistant Commissioner for Criminal Investigations and Ritu Nalubola, Director of the FDA’s Europe Office. Crimi

    9/2/22 1:46:13 PM ET
    $AMLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMLX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Medical Officer Bedrosian Camille L sold $94,418 worth of shares (6,580 units at $14.35), decreasing direct ownership by 4% to 175,756 units (SEC Form 4)

    4 - Amylyx Pharmaceuticals, Inc. (0001658551) (Issuer)

    12/3/25 4:39:50 PM ET
    $AMLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Legal Officer Mazzariello Gina sold $128,669 worth of shares (8,828 units at $14.58), decreasing direct ownership by 6% to 148,141 units (SEC Form 4)

    4 - Amylyx Pharmaceuticals, Inc. (0001658551) (Issuer)

    10/2/25 4:15:13 PM ET
    $AMLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Co-Chief Executive Officer Cohen Joshua B sold $429,469 worth of shares (29,933 units at $14.35), decreasing direct ownership by 0.89% to 3,325,347 units (SEC Form 4)

    4 - Amylyx Pharmaceuticals, Inc. (0001658551) (Issuer)

    10/2/25 4:15:10 PM ET
    $AMLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMLX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Goldman resumed coverage on Amylyx Pharmaceuticals with a new price target

    Goldman resumed coverage of Amylyx Pharmaceuticals with a rating of Buy and set a new price target of $10.00

    7/10/25 8:47:27 AM ET
    $AMLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Guggenheim initiated coverage on Amylyx Pharmaceuticals with a new price target

    Guggenheim initiated coverage of Amylyx Pharmaceuticals with a rating of Buy and set a new price target of $17.00

    6/24/25 7:57:48 AM ET
    $AMLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Citigroup initiated coverage on Amylyx Pharmaceuticals with a new price target

    Citigroup initiated coverage of Amylyx Pharmaceuticals with a rating of Buy and set a new price target of $12.00

    6/17/25 7:48:19 AM ET
    $AMLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMLX
    Financials

    Live finance-specific insights

    View All

    Amylyx Pharmaceuticals Announces New Safety and Tolerability Cohort 1 Data of AMX0114 in ALS from First-in-Human LUMINA Trial

    - AMX0114 was generally well-tolerated, with no treatment-related serious adverse events - Amylyx will proceed with opening enrollment of second cohort - Data are being presented at the 36th International Symposium on ALS/MND Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) ("Amylyx" or the "Company") today announced the presentation of early safety and tolerability data from its Phase 1 LUMINA trial of AMX0114 and results from ongoing work characterizing biomarkers of AMX0114 target engagement at the 36th International Symposium on ALS/MND (MNDA) held from December 5-7 in San Diego, California. AMX0114 was generally well-tolerated in LUMINA trial participants enrolled in cohort 1 (n=12), with

    12/5/25 9:00:00 AM ET
    $AMLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amylyx Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 6, 2025

    Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) ("Amylyx" or the "Company") will report its third quarter 2025 financial results on Thursday, November 6, 2025. Amylyx' senior management team will host a conference call and audio webcast at 8:00 a.m. ET to discuss the financial results and other company updates. To access the conference call, please dial +1 (888) 880-3330 (U.S. & Canada) or +1 (646) 357-8766 (international) at least 10 minutes prior to the start time and ask to be joined into the Amylyx Pharmaceuticals call. A live audio webcast of the call will be available under "Events and Presentations" in the Investor section of the Company's website, https://investors.amylyx.com/events-pr

    10/30/25 9:00:00 AM ET
    $AMLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amylyx Pharmaceuticals Reports Second Quarter 2025 Financial Results

    Completion of recruitment for pivotal Phase 3 LUCIDITY trial of avexitide in PBH expected in 2025, with topline data anticipated in first half of 2026 Cash, cash equivalents, and marketable securities of $180.8 million as of June 30, 2025; cash runway expected through the end of 2026 Management to host conference call and webcast today at 8:00 a.m. Eastern Time   Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) ("Amylyx" or the "Company") today reported financial and business results for the second quarter ended June 30, 2025. "As we look ahead to the second half of the year and into 2026, we remain encouraged by the strength of our pipeline and the continued momentum towards our cl

    8/7/25 7:00:00 AM ET
    $AMLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMLX
    Leadership Updates

    Live Leadership Updates

    View All

    Amylyx Pharmaceuticals, Inc. investors: Please contact the Portnoy Law Firm to recover your losses; April 9, 2024 deadline

    Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, April 08, 2024 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) investors that a lawsuit was filed on behalf of investors that purchased Amylyx securities between November 11, 2022 and November 8, 2023, inclusive (the "Class Period"). Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 310-692-8883 or email: [email protected], to discuss their legal rights, or click here to join the case via www.portnoylaw.com. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors' options for pursui

    4/8/24 6:24:09 PM ET
    $AMLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amylyx Pharmaceuticals Appoints Camille L. Bedrosian, MD, as Chief Medical Officer

    - Dr. Bedrosian brings to Amylyx nearly 30 years of leadership in clinical research, development, and advancing pipeline programs into commercialized global products including as CMO at Ultragenyx, Alexion, and ARIAD Pharmaceuticals Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) ("Amylyx" or the "Company") today announced the appointment of Camille L. Bedrosian, MD, as Chief Medical Officer ("CMO"). In this role, Dr. Bedrosian will lead global functions in medical affairs, regulatory, safety and pharmacovigilance, biometrics, clinical development, and clinical operations. Dr. Bedrosian brings nearly 30 years of experience addressing unmet medical needs for people with rare and serious disease

    11/28/23 7:00:00 AM ET
    $AMLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amylyx Pharmaceuticals Receives CHMP Negative Opinion on its Conditional Marketing Authorisation Application for AMX0035 for the Treatment of ALS in the European Union

    Amylyx will seek re-examination of its Conditional Marketing Authorisation Application Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) ("Amylyx" or the "Company") today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a negative opinion on the application for conditional marketing authorisation of AMX0035 (sodium phenylbutyrate and ursodoxicoltaurine [also known as taurursodiol]), under the trade name ALBRIOZA®, for the treatment of adults with amyotrophic lateral sclerosis (ALS) in the European Union (EU). Today's update follows the Company's May 2023 announcement that the CHMP was trending toward a negative opinion.

    6/23/23 8:14:00 AM ET
    $AMLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMLX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Amylyx Pharmaceuticals Inc.

    SC 13G/A - Amylyx Pharmaceuticals, Inc. (0001658551) (Subject)

    11/12/24 1:22:53 PM ET
    $AMLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Amylyx Pharmaceuticals Inc.

    SC 13G - Amylyx Pharmaceuticals, Inc. (0001658551) (Subject)

    11/4/24 10:56:42 AM ET
    $AMLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Amylyx Pharmaceuticals Inc.

    SC 13G - Amylyx Pharmaceuticals, Inc. (0001658551) (Subject)

    10/25/24 5:38:25 PM ET
    $AMLX
    Biotechnology: Pharmaceutical Preparations
    Health Care